

Annette M Langer-Gould

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/905280/publications.pdf>

Version: 2024-02-01

61
papers

7,999
citations

136885

32
h-index

138417

58
g-index

61
all docs

61
docs citations

61
times ranked

7401
citing authors

#	ARTICLE	IF	CITATIONS
1	B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2008, 358, 676-688.	13.9	2,107
2	Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. <i>New England Journal of Medicine</i> , 2005, 353, 375-381.	13.9	1,010
3	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.5	765
4	Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau Data. , 2012, 16, 37-41.		639
5	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. <i>JAMA Neurology</i> , 2020, 77, 184.	4.5	342
6	Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. <i>Neurology</i> , 2013, 80, 548-552.	1.5	258
7	Incidence of multiple sclerosis in multiple racial and ethnic groups. <i>Neurology</i> , 2013, 80, 1734-1739.	1.5	218
8	Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 1686.	4.9	201
9	Exclusive Breastfeeding and the Risk of Postpartum Relapses in Women With Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 958.	4.9	195
10	Natalizumab Use During the Third Trimester of Pregnancy. <i>JAMA Neurology</i> , 2014, 71, 891.	4.5	168
11	Environmental and genetic risk factors for MS: an integrated review. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1905-1922.	1.7	165
12	Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases. <i>JAMA Neurology</i> , 2014, 71, 1506.	4.5	154
13	Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. <i>JAMA Neurology</i> , 2015, 72, 1132.	4.5	126
14	Pediatric Idiopathic Intracranial Hypertension and Extreme Childhood Obesity. <i>Journal of Pediatrics</i> , 2012, 161, 602-607.	0.9	87
15	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. <i>Annals of Neurology</i> , 2020, 87, 688-699.	2.8	86
16	The American Academy of Neurology's Top Five Choosing Wisely recommendations. <i>Neurology</i> , 2013, 81, 1004-1011.	1.5	85
17	Late Pregnancy Suppresses Relapses in Experimental Autoimmune Encephalomyelitis: Evidence for a Suppressive Pregnancy-Related Serum Factor. <i>Journal of Immunology</i> , 2002, 169, 1084-1091.	0.4	77
18	Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. <i>International Journal of Infectious Diseases</i> , 2020, 99, 291-297.	1.5	77

#	ARTICLE	IF	CITATIONS
19	Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. <i>Neurology</i> , 2020, 94, e1939-e1949.	1.5	73
20	Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility. <i>Neurology</i> , 2017, 89, 1330-1337.	1.5	72
21	Validation of an algorithm for identifying MS cases in administrative health claims datasets. <i>Neurology</i> , 2019, 92, e1016-e1028.	1.5	69
22	Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US. <i>JAMA Neurology</i> , 2021, 78, 1515.	4.5	68
23	Interferon-Î³-Producing T Cells, Pregnancy, and Postpartum Relapses of Multiple Sclerosis. <i>Archives of Neurology</i> , 2010, 67, 51-7.	4.9	62
24	Rituximab, MS, and pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	59
25	MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. <i>Nutrients</i> , 2018, 10, 268.	1.7	58
26	Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	56
27	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019, 15, e1007808.	1.5	48
28	Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. <i>Neurology</i> , 2022, 98, .	1.5	48
29	Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. <i>Clinical Immunology</i> , 2013, 149, 244-250.	1.4	43
30	Breastfeeding, ovulatory years, and risk of multiple sclerosis. <i>Neurology</i> , 2017, 89, 563-569.	1.5	42
31	Validation of the Swedish Multiple Sclerosis Register. <i>Epidemiology</i> , 2019, 30, 230-233.	1.2	42
32	A new way to estimate neurologic disease prevalence in the United States. <i>Neurology</i> , 2019, 92, 469-480.	1.5	40
33	Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. <i>PLoS ONE</i> , 2016, 11, e0149094.	1.1	37
34	Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis. <i>Nutrients</i> , 2018, 10, 184.	1.7	30
35	Multiple sclerosis, rituximab, and COVID-19. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 938-943.	1.7	29
36	Safety of potential breast milk exposure to IFN-Î² or glatiramer acetate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	29

#	ARTICLE	IF	CITATIONS
37	The incidence of clinically isolated syndrome in a multi-ethnic cohort. <i>Journal of Neurology</i> , 2014, 261, 1349-1355.	1.8	28
38	Pregnancy and Family Planning in Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 773-792.	0.4	28
39	Vitamin D, Pregnancy, Breastfeeding, and Postpartum Multiple Sclerosis Relapses. <i>Archives of Neurology</i> , 2011, 68, 310-3.	4.9	26
40	Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 25-30.	0.9	25
41	Vitamin D levels in Hispanics with multiple sclerosis. <i>Journal of Neurology</i> , 2012, 259, 2565-2570.	1.8	23
42	Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
43	Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 377-378.	1.4	20
44	Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. <i>Neurology</i> , 2020, 94, e1548-e1556.	1.5	20
45	Progressive multifocal leukoencephalopathy and multiple sclerosis: Lessons from natalizumab. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 253-258.	2.0	19
46	Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1476-1485.	1.4	18
47	What went wrong in the natalizumab trials?. <i>Lancet, The</i> , 2006, 367, 708-710.	6.3	17
48	The pill times 2: What every woman with multiple sclerosis should know. <i>Neurology</i> , 2014, 82, 654-655.	1.5	11
49	Immunomodulatory Agents and Risk of Postpartum Multiple Sclerosis Relapses. , 2014, 18, 9-13.		11
50	Sex hormones and multiple sclerosis: another informative failure. <i>Lancet Neurology, The</i> , 2016, 15, 22-23.	4.9	10
51	Improving quality, affordability, and equity of multiple sclerosis care. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 980-991.	1.7	10
52	Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level. <i>Annals of Neurology</i> , 2022, 92, 164-172.	2.8	9
53	An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1611-1614.	1.4	8
54	Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	7

#	ARTICLE	IF	CITATIONS
55	The Multiple Sclerosis Treatment Optimization Program. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2146-2154.	1.7	6
56	Vitamin D deficiency is an etiological factor for MS – No. <i>Multiple Sclerosis Journal</i> , 2019, 25, 639-641.	1.4	5
57	Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. <i>JAMA Network Open</i> , 2021, 4, e2136697.	2.8	5
58	Validation of algorithms for identifying outpatient infections in MS patients using electronic medical records. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103449.	0.9	3
59	Pregnancy does not modify the risk of MS in genetically susceptible women. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	2
60	Association Between Vaccines and Neuroinflammation—Reply. <i>JAMA Neurology</i> , 2015, 72, 605.	4.5	1
61	Treating severe MS relapses during pregnancy. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1623-1624.	1.4	0